FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085295554> ?p ?o ?g. }

• W2085295554 endingPage "318" @default.
• W2085295554 startingPage "311" @default.
• W2085295554 abstract "Macular choroidal neovascularization (CNV) is one of the most vision-threatening complications of myopia, which can lead to severe vision loss. The purpose of this study was to evaluate the safety and efficacy of intravitreal ranibizumab in the treatment of myopic CNV.We conducted a prospective, consecutive, interventional study of patients with subfoveal or juxtafoveal CNV secondary to pathologic myopia (PM) treated with intravitreal injection of ranibizumab in the Jules Gonin University Eye Hospital from June 2006 to February 2008. Best-corrected visual acuity (BCVA), optical coherence tomography (OCT), and fluorescein angiography (FA) were performed at baseline and monthly for all patients. Indications for retreatment were loss in BCVA associated either with persistent leakage from CNV shown on FA, and/or evidence of CNV activity on OCT.The study included 14 eyes of 14 patients. The mean spherical equivalent refractive error was -12.5 (range, -8.0 D to -16.0 D). Mean time of follow-up was 8.4 months (range from 3 to 16 months, SD: 3). The mean number of intravitreal injections administered for each patient was 2.36 (SD 1.5). The mean initial visual acuity (VA) was 0.19 decimal equivalent (log-MAR: 0.71, SD: 0.3). A statistically significant improvement to a mean VA of 0.48 decimal equivalent (log-MAR:0.32, SD: 0.25) was demonstrated at the final follow-up. VA improved by a mean of 3.86 (SD 2.74) lines. Nine patients (64%) demonstrated a gain of 3 or more lines. Mean central macular thickness (CMT) measured with OCT was 304 microm (SD: 39) at the baseline, and was reduced significantly at the final follow-up to 153 microm (SD: 23). Average CMT reduction was 170 microm (SD: 57). No injection complications or drug-related side effects were noted during the follow-up period.In this small series of eyes with limited follow-up, intravitreal ranibizumab was a safe and effective treatment for CNV secondary to PM, resulting in functional and anatomic improvements." @default.
• W2085295554 created "2016-06-24" @default.
• W2085295554 creator A5012977512 @default.
• W2085295554 creator A5020750527 @default.
• W2085295554 creator A5028376450 @default.
• W2085295554 creator A5033526157 @default.
• W2085295554 creator A5042634594 @default.
• W2085295554 date "2008-11-29" @default.
• W2085295554 modified "2023-09-27" @default.
• W2085295554 title "Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization" @default.
• W2085295554 cites W110906275 @default.
• W2085295554 cites W115342157 @default.
• W2085295554 cites W1573851418 @default.
• W2085295554 cites W1961426734 @default.
• W2085295554 cites W1966374553 @default.
• W2085295554 cites W1975926216 @default.
• W2085295554 cites W1990049126 @default.
• W2085295554 cites W1991064811 @default.
• W2085295554 cites W1992041797 @default.
• W2085295554 cites W1995540454 @default.
• W2085295554 cites W2006416838 @default.
• W2085295554 cites W2007761826 @default.
• W2085295554 cites W2010145494 @default.
• W2085295554 cites W2023874692 @default.
• W2085295554 cites W2034029819 @default.
• W2085295554 cites W2043057909 @default.
• W2085295554 cites W2051258987 @default.
• W2085295554 cites W2051489551 @default.
• W2085295554 cites W2052236787 @default.
• W2085295554 cites W2069895573 @default.
• W2085295554 cites W2080591818 @default.
• W2085295554 cites W2081727392 @default.
• W2085295554 cites W2083483471 @default.
• W2085295554 cites W2085712747 @default.
• W2085295554 cites W2088166206 @default.
• W2085295554 cites W2091929661 @default.
• W2085295554 cites W2091989599 @default.
• W2085295554 cites W2092226078 @default.
• W2085295554 cites W2096735172 @default.
• W2085295554 cites W2101595734 @default.
• W2085295554 cites W2124415048 @default.
• W2085295554 cites W2154711032 @default.
• W2085295554 cites W2155905635 @default.
• W2085295554 cites W2163040699 @default.
• W2085295554 cites W2166334471 @default.
• W2085295554 cites W2315997705 @default.
• W2085295554 cites W2410906612 @default.
• W2085295554 cites W2915852396 @default.
• W2085295554 doi "https://doi.org/10.1007/s00417-008-0995-0" @default.
• W2085295554 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19043731" @default.
• W2085295554 hasPublicationYear "2008" @default.
• W2085295554 type Work @default.
• W2085295554 sameAs 2085295554 @default.
• W2085295554 citedByCount "67" @default.
• W2085295554 countsByYear W20852955542012 @default.
• W2085295554 countsByYear W20852955542013 @default.
• W2085295554 countsByYear W20852955542014 @default.
• W2085295554 countsByYear W20852955542015 @default.
• W2085295554 countsByYear W20852955542017 @default.
• W2085295554 countsByYear W20852955542018 @default.
• W2085295554 countsByYear W20852955542021 @default.
• W2085295554 countsByYear W20852955542022 @default.
• W2085295554 crossrefType "journal-article" @default.
• W2085295554 hasAuthorship W2085295554A5012977512 @default.
• W2085295554 hasAuthorship W2085295554A5020750527 @default.
• W2085295554 hasAuthorship W2085295554A5028376450 @default.
• W2085295554 hasAuthorship W2085295554A5033526157 @default.
• W2085295554 hasAuthorship W2085295554A5042634594 @default.
• W2085295554 hasBestOaLocation W20852955542 @default.
• W2085295554 hasConcept C118487528 @default.
• W2085295554 hasConcept C141071460 @default.
• W2085295554 hasConcept C2776694085 @default.
• W2085295554 hasConcept C2777802072 @default.
• W2085295554 hasConcept C2778257484 @default.
• W2085295554 hasConcept C2780248432 @default.
• W2085295554 hasConcept C2781100027 @default.
• W2085295554 hasConcept C2781135284 @default.
• W2085295554 hasConcept C2781359195 @default.
• W2085295554 hasConcept C71924100 @default.
• W2085295554 hasConceptScore W2085295554C118487528 @default.
• W2085295554 hasConceptScore W2085295554C141071460 @default.
• W2085295554 hasConceptScore W2085295554C2776694085 @default.
• W2085295554 hasConceptScore W2085295554C2777802072 @default.
• W2085295554 hasConceptScore W2085295554C2778257484 @default.
• W2085295554 hasConceptScore W2085295554C2780248432 @default.
• W2085295554 hasConceptScore W2085295554C2781100027 @default.
• W2085295554 hasConceptScore W2085295554C2781135284 @default.
• W2085295554 hasConceptScore W2085295554C2781359195 @default.
• W2085295554 hasConceptScore W2085295554C71924100 @default.
• W2085295554 hasIssue "3" @default.
• W2085295554 hasLocation W20852955541 @default.
• W2085295554 hasLocation W20852955542 @default.
• W2085295554 hasLocation W20852955543 @default.
• W2085295554 hasOpenAccess W2085295554 @default.
• W2085295554 hasPrimaryLocation W20852955541 @default.
• W2085295554 hasRelatedWork W1987334421 @default.
• W2085295554 hasRelatedWork W2039482367 @default.
• W2085295554 hasRelatedWork W2079523484 @default.

• next